Studies new biological markers to help diagnose and manage prostate cancer
Observes new blood markers for prostate cancer diagnosis in adult men.
Plain-language title generated from the registry record
Registry title: The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population
Key facts
- Where
- Shatin, Hong KongSee the site
Where in Hong Kong
- Prince of Wales HospitalShatin, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT03893929
- Record updated
- 27 October 2026
- Original description
Prostate cancer (PC) is highly prevalent worldwide and is currently the 3rd most commonly diagnosed prostate cancer in Hong Kong male population with more than 1600 new cases diagnosed per year. However, the current use of serum PSA as a diagnostic marker is unsatisfactory. Many patients has elevated serum PSA is actually due to other causes and also the level of serum PSA do not correlate with the staging and grading of prostate cancer. Moreover, the current risk stratification system, based on PSA, clinical staging and Gleason score is of only limited value, as a significant proportion of patients with high-risk nonmetastatic PC have incurable disease due to locally advanced and/or occult metastasis,, whilst others with indolent disease may never suffer morbidity or mortality from PC.Read full original descriptionShow less
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population
Prostate cancer (PC) is highly prevalent worldwide and is currently the 3rd most commonly diagnosed prostate cancer in Hong Kong male population with more than 1600 new cases diagnosed per year. However, the current use of serum PSA as a diagnostic marker is unsatisfactory. Many patients has elevated serum PSA is actually due to other causes and also the level of serum PSA do not correlate with the staging and grading of prostate cancer. Moreover, the current risk stratification system, based on PSA, clinical staging and Gleason score is of only limited value, as a significant proportion of patients with high-risk nonmetastatic PC have incurable disease due to locally advanced and/or occult metastasis,, whilst others with indolent disease may never suffer morbidity or mortality from PC.
Therefore, in order to improve patient management and outcome, there is a need to identify newer markers and also validate some potential markers in Chinese population.
Inclusion: Adult Chinese male patients with age > 18 years old; Clinical suspected to have prostate cancer, based on abnormal digital rectal examination or elevated serum PSA level.
Exclusion: Patient refused or unable to provide consent for the study.